Curcumin as adjuvant therapy to improve remission in myeloma patients: A pilot randomized clinical trial

Curcumin as adjuvant therapy to improve remission in myeloma patients: A pilot randomized clinical trial

Background: The treatment for ineligible transplant multiple myeloma is melphalan prednisone. Curcumin has an anti-inflammatory and antiangiogenesis in cancer-directed to nuclear factor-kappa B (NF-kB) pathway. Interleukin 6 (IL-6), vascular endothelial growth factor  (VEGF), tumor necrosis factor-a...

Full description

Bibliographic Details
Main Authors: Damai Santosa, Catharina Suharti, Ignatius Riwanto, Edi Dharmana, Eko Adhi Pangarsa, Budi Setiawan, Suyono Suyono, Mika Lumban Tobing, Suhartono Suhartono, Soeharyo Hadisaputro
Format: Article
Language:English
Published: Babol University of Medical Sciences 2022-02-01
Series:Caspian Journal of Internal Medicine
Subjects:
myeloma
remission
nf-κb
vegf
tnf-α
and il-6
Online Access:http://caspjim.com/article-1-2115-en.html

Internet

http://caspjim.com/article-1-2115-en.html

Similar Items